Disclosed is treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1 and an antisense nucleic acid that suppresses expression of IL-20R1本發明係有關於一種與IL-20受體所引導之訊息途徑有關之病症(如骨質疏鬆、腎臟衰竭或糖尿病性腎病變)的治療,其係使用抑制IL-20受體活性之藥劑,如經由結合IL-20R1而中和IL-20受體之抗體、以及抑制IL-20R1表現之反義核酸。